Eur Rev Med Pharmacol Sci 2021; 25 (13): 4597-4610

DOI: 10.26355/eurrev_202107_26252

How to define a quadruple aim framework to assess value in critical pathway of the patients with Clostridioides difficile infection

A.G. de Belvis, A. Fratini, C. Angioletti, A. Morsella, R. Ruggeri, G. Pepe, G. Ianiro, C. Settanni, A. Gasbarrini, G. Cammarota

Department of Life Sciences and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy. carmen.angioletti92@gmail.com


OBJECTIVE: The study aims to define the set of Key Performance Indicators (KPIs) required to assess the Value delivered by managing patients with Clostridioides difficile infection through a Critical Pathway. We used the quadruple aim Value-Based approach, and we validated the set of KPIs with the Delphi method.

MATERIALS AND METHODS: The study focuses on patients on board a Critical Pathway on Clostridioides difficile Infection and targeted towards a Fecal Microbiota Transplantation (FMT). FMT has been used to successfully treat recurrent Clostridium difficile infection. A two-round e-Delphi survey collecting data was conducted in 2019-2020 to validate the Value-Based evaluation tool. The Value-Based criteria taken into account are Clinical Outcomes, Experience of Care, Per-capita cost, Physician’s burnout.

RESULTS: The two rounds led to the validation of 50 items, and four primary clinical outcomes (Mortality rate, length of stay, readmission and complications related to the illness).

CONCLUSIONS: The evaluation tool included is validated in its totality and can provide a comprehensive overview of the Value created by the Critical pathway for patients with Clostridioides difficile. We can extend the approach illustrated in this study can also to evaluate other Critical pathways.

Free PDF Download

To cite this article

A.G. de Belvis, A. Fratini, C. Angioletti, A. Morsella, R. Ruggeri, G. Pepe, G. Ianiro, C. Settanni, A. Gasbarrini, G. Cammarota
How to define a quadruple aim framework to assess value in critical pathway of the patients with Clostridioides difficile infection

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 13
Pages: 4597-4610
DOI: 10.26355/eurrev_202107_26252